Project Grant R01CA316454
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $413K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $827,942.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate a novel inhibitory receptor that regulates the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The key objectives are to: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic...
- The National Cancer Institute awarded The Washington University $548,528 under the Cancer Treatment Research program (CFDA 93.395) on September 3, 2026, to enhance CAR-T cell therapy for relapsed or refractory large B cell lymphoma. The recipient will conduct a Phase 1B clinical trial evaluating early and repeated dosing schedules of NT-I7, a long-acting interleukin-7 therapeutic, administered following axicabtagene ciloleucel or lisocabtagene maraleucel infusion in patients with relapsed or...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded Case Western Reserve University $393,812 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and optimize photobiomodulation (PBM)–enhanced CAR-T cell therapy. The project investigates whether visible to near-infrared light can enhance the metabolic fitness and durability of chimeric antigen receptor T cells without genetic modification. Aim 1 systematically optimizes...
- The National Cancer Institute awarded Case Western Reserve University $164,190 under the Cancer Research Manpower program (CFDA 93.398) on January 16, 2026, to investigate the role of B-cell activating factor (BAFF) in adverse events associated with chimeric antigen receptor (CAR)-T cell therapy. The research examines BAFF's contribution to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), the two most common and potentially life-threatening...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...
- The National Cancer Institute awarded Case Western Reserve University $100,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop real-time monitoring of nanobubble-labeled chimeric antigen receptor T cell trafficking via contrast-enhanced ultrasound imaging. The award funds research to refine nanobubble labeling protocols for prostate-specific membrane antigen (PSMA)-targeting CAR-T cells, enhancing imaging duration and stability to enable extended...
- The National Cancer Institute awarded Weill Medical College of Cornell University $716,183 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate and target co-inhibitory and co-stimulatory molecules in CAR T-cell therapies. The award funds research to overcome clinical barriers in adoptive cell therapies with chimeric antigen receptors, which show promise for cancer treatment but face challenges including insufficient T-cell persistence, antigen escape, and...
- The National Cancer Institute awarded Weill Medical College of Cornell University $435,827 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop autologous lymph node T cells engineered to overcome treatment-resistant lung cancer. The research addresses the limited effectiveness of adoptive T-cell therapy in solid tumors by utilizing polyclonal cohorts of multipotent T cells derived from tumor-draining lymph nodes rather than peripheral blood. Prior work...
- The National Institutes of Health National Cancer Institute awarded The Washington University $399,829 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to conduct rational design of next-generation engineered T cells for enhanced cancer immunotherapy. The research addresses limited persistence of engineered T cells in cancer treatment by harnessing 4-1BB (CD137/TNFRSF9), a co-stimulatory molecule, through structure-informed protein design. Current 4-1BB chimeric...
- The National Cancer Institute awarded Cleveland Clinic Lerner College of Medicine of Case Western Reserve University $640,775 on June 22, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a co-clinical trial investigating mechanisms by which intratumoral bacteria drive immunosuppression and immune checkpoint inhibitor resistance in head and neck squamous cell carcinoma. The recipient will define how intratumoral bacterial load modulates the immunosuppressive tumor immune...